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ABSTRACT
Background: Metabolic reprogramming is one of the hallmarks of cancer. The 
hyperglycolytic phenotype is often associated with the overexpression of metabolism-
associated proteins, such as monocarboxylate transporters (MCTs). MCTs are little 
explored in germ cell tumors (GCTs), thus, the opportunity to understand the relevance 
of these metabolic markers and their chaperone CD147 in this type of tumor arises. 
The main aim of this study was to evaluate the expression of MCT1, MCT2, MCT4 and 
CD147 in testicular GCT samples and the clinicopathological significance of these 
metabolism related proteins. 
Results: MCT1, MCT4 and CD147 were associated with higher stages, higher M 
and N stages and histological type, while MCT4 was also associated with higher risk 
stratification, presence of vascular invasion, and lower overall and event free survival. 
MCT4 silencing in JEG-3 had no significant effect in cell viability, proliferation and 
death, as well as extracellular levels of glucose and lactate. However, MCT4-silenced 
cells showed an increase in migration and invasion.
Conclusion: The proteins herein studied, with the exception of MCT2, were 
associated with characteristics of worse prognosis, lower global and event free 
survival of patients with GCTs. Also, in vitro MCT4 silencing stimulated cell migration 
and invasion.
Materials and Methods: Immunohistochemical expression was evaluated on 
samples from 149 adult patients with testicular GCT, arranged in Tissue Microarrays 
(TMAs), and associated with the clinicopathological data. Also, MCT4 silencing studies 
using siRNA were performed in JEG-3 cells.
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INTRODUCTION
Although testicular germ cell tumors (TGCTs) are 
relatively rare neoplasms, they are the most frequent solid 
tumors affecting young males [1, 2]. Importantly, the 
natural history of these tumors has changed over the past 
three decades, thanks to platinum-based chemotherapy 
regimens, with current 5-year overall survival rates 
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over 90% regardless of histological type (seminoma and 
nonseminomatous) and cure rates over 90% in the low 
risk group. Although the majority of patients with TGCTs 
have good responses to treatment, some of them resist 
to therapy and present disease progression (reviewed in 
[3, 4]). Therefore, it is important to better understand the 
biological heterogeneity of TGCTs, in order to optimize 
treatment by exploring new pathways involved in tumor 
development and progression.
Nearly all TGCTs present the isochromosome 12p, 
which has been pointed as the triggering event leading 
to invasive growth in TGCTs. However, the precise 
functional mechanisms involving isochromosome 12p 
as a player in TGCTs are yet to be described (reviewed 
in [5]). Despite this lack of information, other relevant 
biological characteristics involved in the multistep 
development of human tumors, as proposed by Hanahan 
and Weinberg [6], should be considered in the pursuit to a 
better understanding of the biological features of TGCTs. 
In this context, the reprogramming of energy metabolism, 
recently described as one of the hallmarks of cancer cells 
[6, 7], emerges as a promising candidate.
Malignant cells tend to have a hyperglycolytic 
phenotype, a metabolic reprogramming in which cancer 
cells have a preference for energy production through 
glycolysis, even in the presence of oxygen, a phenomenon 
called the Warburg effect [8, 9]. This phenotype leads to 
greater consumption of glucose and produces more lactate 
than the normal metabolic profile, which depends mostly 
on oxidative phosphorylation [6–9]. To avoid intracellular 
acidification due to this altered metabolism, some proteins 
are upregulated, including monocarboxylate transporters 
(MCTs), which are also responsible for lactate transport 
[10]. MCTs belong to a family that comprises 14 different 
isoforms, from which only MCT1-4 have been described 
as lactate transporters: isoforms 1 and 4 are mainly 
associated with lactate efflux and their main chaperone is 
CD147 [11–13], MCT2 is involved in lactate influx and its 
chaperone is gp70 [14, 15]. In fact, many different types 
of cancer overexpress MCT1, MCT4 and CD147, and this 
overexpression is associated with worse prognosis [16–
24]. As pointed out by many studies, these proteins may 
play a relevant role as prognostic markers and be explored 
as possible therapeutic targets [24–31].
Although studies evaluating MCTs in TGCTs are 
lacking, there is evidence that these tumors are highly 
glycolytic, as they overexpress glucose transporter 
3 (GLUT3) [32, 33], a protein often expressed by 
malignant neoplasms [33, 34], and, importantly, their 
high glucose consumption rates are demonstrated by 
18F-Fluorodeoxyglucose positron emission tomography 
studies [35–37]. 
Since MCTs need to be more explored, including 
in TGCTs, it is important to evaluate the relevance of 
these metabolic markers and the chaperone CD147 
in this type of tumor. Therefore, the aims of this study 
were to evaluate the expression of MCT1, MCT2, MCT4 
and CD147 in normal tissues and TGCTs, using tissue 
microarrays (TMAs), to validate the TMA method for the 
study of these proteins in a heterogeneous type of tumor, 
to compare the expression in tumors with normal tissue, 
to correlate the expression with clinicopathological data, 
and to further explore the contribution of MCTs for tumor 
aggressiveness using GCT in vitro models. 
RESULTS
Immunohistochemistry expression and cutoffs
The immunohistochemical expression was 
graduated in extension (percent of positive cells) and 
intensity (negative/weak/moderate/intense). Cutoffs for 
positivity of each marker were defined based on the area 
under the ROC curve, considering the sum of scores and 
the occurence of clinical event (recurrence, progression 
or death). For MCT1 and MCT4, the score with best 
sensitivity and specificity was 6, while for MCT2 it was 3 
and for CD147 it was 5 (Table 1).
As can be observed in Figure 1, MCT1, MCT4 and 
CD147 were observed at the plasma membrane, while 
MCT2 was mostly detected only at the cytoplasm. 
Validation of TMA method
Analysis of agreement between TMA and whole 
tissue sections showed an accuracy for TMA method of 
79.3% for MCT1, 100% for MCT2, 76.6% for MCT4 and 
79.3% for CD147. 
Clinicopathological significance of MCTs and 
CD147
When compared to paired normal tissue samples 
(Figure 2), TGCTs significantly overexpressed MCT4 
(p = 0.001) and CD147 (p = 0.001). 
Table 2 shows the associations between the 
expression of the metabolism related proteins and 
the clinicopathological parameters of the patients. 
MCT1 expression showed a statistically significant 
association with higher N stages (p = 0.015), higher M 
stage (p = 0.002), stages higher than I (p = 0.001), and 
nonseminomatous histology (p < 0.001). MCT4 was 
associated with higher T stages (p = 0.004), higher M stage 
(p = 0.037), stages higher than I (p = 0.045), presence of 
vascular invasion (p = 0.002), nonseminomatous histology 
(p < 0.001), and higher International Germ Cell Cancer 
Collaborative Group (IGCCG) risk stratifications (p = 
0.030). CD147 was associated with stages higher than I 
(p = 0.003), higher N stages (p = 0.022), higher M stage 
(p = 0.020), and nonseminomatous histology (p < 0.001). 
In opposition, MCT2 showed no association with the 
clinicopathological data.
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Table 1: Markers’ cutoffs based on the area under the ROC curve, and their classification measures
Marker Cutoff Sensitivity (%) Specificity (%) PPV NPV Area under ROC curve (CI)
MCT1 ≥6 64.0 53.8 22.5 87.7 0.597 (0.479–0.715)
MCT2 ≥3 14.3 84.4 16.7 81.8 0.509 (0.264–0.754)
MCT4 ≥6 69.6 55.1 23.2 90.3 0.647 (0.537–0.758)
CD147 ≥5 35.0 77.5 25.9 84.1 0.557 (0.416–0.698)
CI – Confidence interval; PPV – Positive predictive value; NPV – Negative predictive value.
Figure 1: Immunohistochemical expression of MCT1 (A), MCT2 (B), MCT4 (C), CD147 (D), in seminomas. MCT2 shows cytoplasmic 
staining while the other proteins show an evident plasma membrane expression.
Figure 2: Frequency of plasma membrane expression of MCT1, MCT2, MCT4 and CD147 in TGCTs and normal 
testicular tissue. McNemar's test was used to assess differences of expression frequency between tumor and normal tissue. *p = 0.001.
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MCTs, CD147 and survival
Kaplan-Meier analysis (Figure 3) revealed that 
MCT4 positive expression was significantly associated 
with shorter overall (p = 0.011) as well as shorter 
event-free survival (p = 0.027). Other proteins were not 
significantly associated with survival. None of the markers 
were associated with survival in multivariate analysis by 
Cox regression (data not shown).
In vitro experiments
To further elucidate the possible contribution of 
MCT4 for tumor aggressiveness, in vitro MCT4 silencing 
studies were performed. 
First, the germ cell tumor cell lines JEG-3 and 
NTERA-2 were characterized for MCT and CD147 
expression. As can be seen in Figure 4A, MCT1, MCT4 
and CD147 were expressed at the plasma membrane of 
both cell lines, although MCT4 was only detected in a 
small proportion of NTERA-2 cells. In opposition, MCT2 
was absent from both JEG-3 and NTERA-2 cell lines. 
These results were validated by Western-blot (Figure 
4B). Based on these results, JEG-3 cells were selected for 
MCT4 silencing using siRNA (Figure 5A). As depicted in 
Figure 5, MCT4 silencing had no effect on extracellular 
amounts of glucose (Figure 5B) and lactate (Figure 5C), as 
well as no effect of cell viability (Figure 5D), proliferation 
(Figure 5E) and death (Figure 5F). However, as can 
be seen in Figure 6, MCT4-silenced cells showed an 
important increase in migration (Figure 6A) and invasion 
(Figure 6B).
DISCUSSION
In the present study, the expression of the 
metabolism related proteins MCT1, MCT2, MCT4 and 
Table 2: Association of MCT1, MCT2, MCT4 and CD147 expression with clinicopathological parameters
MCT1 MCT2 MCT4 CD147
n Positive (%) p n Positive (%) p n Positive(%) p n Positive (%) p
T stage 0.148 0.081* 0.004 0.069*
T1 85 35 (41.2) 85 5 (5.9) 83 29 (34.9) 82 25 (30.5)
T2+T3+T4 58 31 (53.4) 58 0 (0.0) 57 34 (59.6) 57 26 (45.6)
N stage 0.015 1.000* 0.094 0.022*
N0 84 33 (39.3) 83 4 (4.8) 81 33 (40.7) 80 23 (28.8)
N1+N2+N3 62 37 (59.7) 62 2 (3.2) 62 34 (54.8) 60 29 (47.5)
M stage 0.002 1.000* 0.037 0.020*
M0 122 52 (42.6) 121 5 (4.1) 120 52(43.3) 118 39 (33.1)
M1 25 19 (76.0) 25 1 (4.0) 24  16(66.7) 24 14 (58.3)
Stage 0.001 1.000* 0.045 0.003*
I 74 26 (35.1) 73 3 (4.1) 72 28 (38.9) 71 18 (25.4)
IS+II+III+IV 73 45 (61.6) 73 3 (4.1) 72 40 (55.6) 71 35 (49.3)
Vascular invasion 0.889 0.178* 0.002 0.493*
No 99 45 (45.5) 99 6 (6.1) 97 35 (36.1) 96 33 (34.4)
Yes 43 19 (44.2) 43 0 (0.0) 42 27 (64.3) 42 17 (40.5)
Histology <0.001 0.114* <0.001 <0.001*
Seminoma 75 17 (22.7) 75 1 (1.3) 73 23 (31.5) 73 10 (13.7)
Nonseminomatous 74 54 (73.0) 73 5 (6.8) 73 46 (63.0) 71 43 (60.6)
IGCCG Risk 0.194* 0.452* 0.030* 0.801*
Low 45 26 (57.8) 45 2 (4.4) 45 21 (46.7) 44 22 (50.0)
Intermediate 11 7 (63.6) 11 0 (0.0) 11 8 (72.7) 11 7 (63.6)
High 10 9(90.0) 10 1(10.0) 9 8(88.9) 9 5 (55.6)
Recurrence 0.108 0.542* 0.303 0.682*
No 125 55 (44.0) 125 5 (4.0) 123 56 (45.5) 122 44 (36.1)
Yes 17 11 (64.7) 17 1 (5.9) 17 10 (58.8) 17 7 (41.2)
Progression 0.468* 0.287* 0.725* 1.000*
No 68 40 (58.8) 68 2 (2.9) 68 37 (54.4) 67 31 (46.3)
Yes 8 6 (75.0) 8 1 (12.5) 8 5 (62.5) 8 4 (50.0)
*Fisher’s exact test.
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CD147 was characterized in a representative sample of 
testicular TGCTs.
The use of the area under ROC curve to access the 
cutoffs for positivity allowed the definition of scores better 
associated with clinical events of recurrence, progression 
and death. The cutoffs defined were MCT1 ≥6, MCT2 ≥3, 
MCT4 ≥6 and CD147 ≥5. With the exception of MCT2, 
these scores differ from the ones used in previous studies 
by our group, where scores ≥3 were defined as positive [19, 
38–51]. We believe that this approach for cutoff definition, 
which may vary among tumor type but is more illustrative 
of possible clinical significance, may bring results that, 
otherwise, may be masked by an inadequate cutoff.
TMA method demonstrated an accuracy of 79.3% 
for MCT1, 100% for MCT2, 76.6% for MCT4 and 79.3% 
for CD147. A potential limitation of this method is tumor 
heterogeneity, a common event in GCTs. However, in this 
study, cores in triplicate for each histological subtype were 
used, in attempt to minimize this limitation. This study 
is similar to others in the way that evaluated GCTs by 
immunohistochemistry on TMAs with cores in triplicate 
[32, 52]; however, those and other previous studies using 
TMAs to organize GCTs did not compare TMAs with 
whole sections [32, 52, 53]. The present study is unique 
since it used triplicate cores for each histological subtype 
and compared 31 whole sections in a sample of 149 
Figure 3: Overall and event-free survival curves of TGCTs’ patients. Only significant results are shown. Continuous line refers 
to positive expression while interrupted line refers to negative expression. (A) Overall survival associated with MCT4 plasma membrane 
expression; (B) Event-free survival associated with MCT4 plasma membrane expression.
Figure 4: Expression of monocarboxylate transporters and the chaperone CD147 in the germ cell tumor cell lines 
JEG-3 and NTERA-2. (A) Immunocytochemical expression of MCT1, MCT2, MCT4 and CD147; (B) Detection of MCT1, MCT2, 
MCT4 and CD147 by Western blot, in cell lysates.
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cases on TMAs, achieving acceptable accuracy values, 
considering tumor heterogeneity.
MCT4 and CD147 overexpression in TGCTs, when 
compared to normal tissue, suggests that these tumor cells 
present a high lactate efflux, most probably as a result of a 
hyperglycolytic phenotype. These findings are in line with 
previous data that associate the overexpression of these 
proteins with hyperglycolytic phenotypes in other tumor 
Figure 5: MCT4 silencing had no effect on metabolic parameters as well as viability, proliferation and death of JEG-3 
cells. (A) Western blot results for MCT4 expression after SLC16A3 knockdown, using 10 nM siRNA, for 72 hours, showing an effective 
silencing of MCT4 expression. Scramble siRNA was used as negative control and β-actin was used as loading control. Extracellular 
amounts of glucose (B) and lactate (C) levels were quantified in culture medium obtained after 24 hours, normalized by total biomass 
(obtained using SRB assay) and are represented as the mean of three independent experiments in triplicate ± SEM. Cell viability was 
evaluated using SRB assay (D) while cell proliferation was evaluated using BrdU incorporation (E). Results were obtained after 24 
hours of cell culture, normalized as the percentage of the negative control (scramble siRNA), and are represented as the mean of three 
independent experiments in triplicate ± SEM. Cell death was evaluated using flow cytometry analysis after Annexin V/PI staining (F). 
Results were obtained after 24 hours and are represented by the mean percentage of double stained cells (late apoptosis/necrosis) from two 
independent experiments ± SEM.
Figure 6: MCT4 silencing increases cell migration and invasion of JEG-3 cells. Cell migration was evaluated using ThinCert 
Cell Cultures Inserts (Greiner Bio-One) (A). Results were obtained after 24 hours and are represented as the mean of two independent 
experiments in duplicate ± SEM (left panel). Representative images of the migration assay are shown (right panel). **p = 0.0016 compared 
to control (scramble siRNA). Cell invasion was evaluated using Corning BioCoat Matrigel Invasion Chamber with BD Matrigel Matrix 
(B). Results were obtained after 24 hours and are represented as the mean of three independent experiments in duplicate ± SEM (left panel). 
Representative images of the invasion assay are shown (right panel). **p = 0.0027 compared to control (scramble siRNA).
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types, being associated with malignant behavior and tumor 
aggressiveness [17, 19, 21, 22, 28, 54]. Although not 
statistically significant, the higher expression of MCT2 in 
normal tissue than in TGCTs is consistent with its function 
in lactate uptake, and with the oxidative phenotype of 
normal tissues [11, 14, 19, 55].
The association of MCT1, MCT4 and CD147 
expression with characteristics of worse prognosis, such 
as nonseminomatous histology, higher stages, higher 
metastasis occurrence, vascular invasion and higher 
risk stratification, reflect the function of these proteins 
in lactate efflux, in maintaining the extracellular acid 
pH, and, as a result, in glycolytic phenotype and tumor 
aggressiveness. Despite the lack of studies of these 
proteins on TGCTs, our findings corroborate previous 
evidence of the association between their expression and 
worse prognosis in other types of cancer with glycolytic 
phenotype [16, 18, 54, 56, 57].
MCT4 expression was associated with lower overall 
and event free survival in univariate analysis, which is 
consistent with previous findings in other solid tumors [16, 
18, 22, 54, 56–58]. However, none of the markers were 
associated with lower survival in multivariate analysis.
Previous studies have shown that, in general, in vitro 
MCT silencing is associated with a decrease in tumor cell 
aggressiveness, by means of a decrease in cell viability, 
proliferation, migration and invasion as well as an increase 
in cell death (reviewed in [24]), which would support the 
findings obtained in the TGCTs human samples. Herein, 
MCT4 silencing did not affect cell viability, proliferation 
or death. In fact, this is not an unexpected result, as the 
cell line used for MCT4 silencing also express MCT1 
at the plasma membrane, which is probably providing 
the efflux of lactate, compensating for the lack of 
MCT4. Actually, accordingly, extracellular glucose and 
lactate levels were not affected by MCT4 silencing, an 
observation already made in other in vitro tumor model 
[28]. To validate this hypothesis, an attempt to a double 
MCT1/MCT4 silencing approach was made, however, 
the different timings of MCT1 versus MCT4 silencing 
using siRNA, compromised the efficiency of the double 
silencing (Supplementary Figure 1A and 1B). Other 
experimental approaches, such as stable silencing or gene 
editing, are warranted to further explore this hypothesis. 
Nevertheless, although with no influence on extracellular 
glucose and lactate, cell viability, proliferation and death, 
MCT4 silencing importantly increased cell migration and 
invasion. Previous studies have showed a role of MCT1 
and MCT4 in tumor cell migration [23, 59–63] and 
invasion [62, 64], which seems to be independent from 
transporter activity [60]. Following this line of evidence, 
and considering that the result expected from MCT4 
silencing is a reduction in cell migration and invasion, 
one can hypothesize that the increase in these parameters 
may result from an increase in MCT1 expression in 
response to MCT4 silencing. However, neither MCT1 
nor CD147 expression was altered by MCT4 silencing 
(Supplementary Figure 1D). Additional studies are needed 
to further explore the specific contribution of MCT4 for 
tumor cell migration and invasion in germ cell tumors and 
others.
In conclusion, the present study validates TMA as 
a useful method to study MCTs and CD147 in TGCTs. 
Also, it demonstrates the overexpression of these proteins 
in tumor cells, and its association with parameters of 
worse prognosis and shorter survival rates. Finally, in 
vitro studies showed that individual MCT4 silencing in 
a cell line positive for both MCT1 and MCT4 does not 
decrease the main parameters of tumor aggressiveness. 
This study may contribute to the knowledge on the 
clinicopathological significance of these metabolism-
related proteins and paves the way for additional studies to 
explore them as potential prognostic markers and possible 
therapeutic targets in TGCTs.
MATERIALS AND METHODS
Cases selection
A total of 149 cases of TGCTs were selected from 
the Department of Pathology of Barretos Cancer Hospital. 
Only samples from primary tumors, collected prior to 
chemotherapy and with enough formalin fixed paraffin 
embedded material, were selected.
The clinicopathological data collected included 
age, date of diagnosis, histological types, grading 
(when applicable), staging (TNM), presence of vascular 
invasion, IGCCG risk stratification, and dates of surgery, 
chemotherapy, recurrence and death. 
Patients’ mean age was 32.3 years (ranging from 18 
to 73 years) and most of them were Caucasian (80.2%). 
As depicted in Table 3, half of the patients presented 
with stage I neoplasms (50.3%) and, among stages II and 
III, most of the patients were low IGCCG risk (68.2%). 
Seminoma was the most frequent histological type 
(50.3%). The most frequent chemotherapy treatment used 
was Bleomycin, Etoposide and Cisplatin (BEP) (42.8%) 
followed by Etoposide and Cisplatin (EP) (9.7%) and 
44.8% of the patients did no receive chemotherapy. The 
median follow up was 40.3 months and the majority of 
patients were alive and free of disease at the end of the 
study (85.9%). 
The present study was approved by the Local Ethic 
Committee (number 541235).
TMA construction and validation
All the cases were reviewed by an experienced 
pathologist (ECAS) for diagnostic confirmation and 
demarcation of tumor areas for TMA cores. Each tumor 
histological subtype and corresponding normal tissues 
were selected (when available and sufficient) for triplicate 
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cores of 1.0 mm. Tissue cores of liver, kidney and placenta 
were used as controls for TMA orientation.
For TMA validation, 31 cases were randomly 
selected based on sample calculation, with a confidence 
interval of 95%. For these 31 cases, immunohistochemistry 
was performed on both TMA and whole sections, and the 
results compared.
Immunohistochemistry
Immunohistochemistry was performed on TMA 
samples and whole sections, according to manufacturer’s 
instructions and as previously described [19]. MCT1 
immunohistochemistry was performed using a polymer 
system (UltraVision LP Detection System: HRP Polymer, 
Lab Vision Corporation, Fremont, CA). MCT2 and 
MCT4 immunohistochemistry was performed using 
the streptavidin-biotin-peroxidase complex principle 
(Ultravision Detection System: Anti-polyvalent, HRP, 
Lab Vision Corporation, Fremont, CA). For CD147, the 
avidin-biotin-peroxidase complex method (VECTASTAIN 
Elite ABC kit R.T.U., Vector, Burlingame, CA) was 
used. For details on each antibody, see Table 4. Slides 
were counterstained with hematoxylin and permanently 
mounted. Colon carcinoma tissue was used as positive 
control for all antibodies. 
Plasma membrane expression was evaluated semi-
quantitatively for extension and semi-qualitatively for 
intensity. For extension, the grading was: 0: no positive 
cells; 1: <5% of positive cells; 2: 5–50% of positive cells; 
3: >50% of positive cells. Staining intensity was graded 
as follows: 0: negative; 1: weak; 2: moderate; 3: intense. 
The final score was obtained by the sum of both grades 
(minimum 0 and maximum 6).
TMA and whole sections immunostains were 
evaluated by two experienced pathologists independently 
(ECAS and CS-N). Discordant cases were reviewed and 
scored in consensus.
Table 3: Clinicopathological parameters of the patients
n (%)
Histological type
Yolk sac 1 (0.7)
Choriocarcinoma 2 (1.3)
Embryonal Carcinoma 8 (5.4)
Immature Teratoma (grade I) 2 (1.3)
Seminoma 75 (50.3)















No Chemotherapy 65 (44.8)
Status – post treatment
Alive and disease free 128 (85.9)
Alive and in treatment 5 (3.4)
Cancer related death 13 (8.7)
Death from other causes 3 (2.0)
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Cell lines and cell culture 
The germ cell tumor cell lines NTERA-2 and JEG-
3 were used in this study. Both cell lines were used for 
protein characterization using immunocytochemistry and 
Western Blotting and JEG-3 cell line was used for in vitro 
studies. The cell lines were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM 1×, High Glucose, 
Gibco, Invitrogen) supplemented with 10% fetal bovine 
serum, FBS (Gibco, Invitrogen) and 1% penicillin-
streptomycin solution (Gibco, Invitrogen) at 37° C and 5% 
CO2. The cells were authenticated by genotyping (panel of 
8 short tandem repeat loci) as previously described [65], 
and validated as mycoplasma negative. 
Paraffin cytoblock and immunocytochemistry
Paraffin cytoblocks were made from concentrated 
cell suspensions by centrifuging fresh cell suspensions 
at 1500 rpm for 5 min. Cell pellets were incubated with 
formaldehyde 10% for 1 hour and recentrifuged. Fixed 
pellets were included in agarose 2% PBS 1× at 60° C, 
homogenized and centrifuged at 13000 rpm for 2 min. Solid 
agarose cell pellets were cuted in two halfs for processing 
and paraffin inclusion. Immunocytochemistry for MCT1, 
MCT2, MCT4 and CD147 was performed in 4 µm 
cytoblock sections, as described for immunohistochemistry 
for human samples. 
Western blotting
NTERA-2 and JEG-3 GCTs cell lines were grown 
to 70–80% confluence, washed in cold PBS and then 
scrapped and homogenized in lysis buffer containing 50 
mM Tris (pH = 7.5), 150 mM NaCl, 0.1 mM EDTA, 1% 
Triton X-100 and 1% NP40, supplemented with 1:10 
protease inhibitors (cOmplete Protease Inhibitor Cocktail, 
Roche) according to the manufacturer’s instructions. 
The lysates were incubated on ice for 15 min and 
then centrifuged at 13000 rpm for 15 min at 4° C. The 
supernatants were collected and protein concentration was 
determined using the Bradford assay (Bio-Rad Protein 
Assay kit, Bio-Rad). Proteins were dissolved in sample 
buffer (Laemmli 2× Concentrate, Sigma-Aldrich) and 
boiled for 5 min at 95°C. Aliquots of 20 µg of total protein 
were separated on 10% polyacrylamide gel by SDS-PAGE 
and transferred onto a nitrocellulose membrane (Protran, 
Amersham, GE Healthcare) in 25 mM Tris-base/glycine 
buffer by TransBlot Turbo transfer (Bio-Rad). Membranes 
were blocked with 5% non-fat dry milk in TBS/0.1% 
Tween (TBS-T; pH = 7.6) for 1 hour at room temperature. 
After overnight incubation at 4° C with the primary 
antibodies (dilution in TBS-T, 5% BSA) for MCT1 (1:200 
dilution, H-1, sc-365501, Santa Cruz Biotechnology), 
MCT2 (1:1200 dilution, ab81262, Abcam), MCT4 (1:2000 
dilution, H-90, sc-50329, Santa Cruz Biotechnology) 
and CD147 (1:250 dilution, 1.BB.218, sc-71038, Santa 
Cruz Biotechnology), membranes were washed in 
TBS-T and incubated with anti-rabbit (sc-2020, Santa 
Cruz Biotechnology) or anti-mouse (sc-2031, Santa 
Cruz Biotechnology) secondary antibodies coupled to 
horseradish peroxidase (1:5000 dilution in TBS-T, 5% 
non-fat dry milk). The bound antibodies were visualized 
by chemiluminescence (Supersignal West Femto kit, 
Pierce) in ImageQuant LAS 4000 mini (GE Healthcare). 
β-Actin was used as loading control at 1:2000 dilution 
(8H10D10, Cell Signaling Technology). 
RNA interference and transfection 
Silencing experiments were performed using 10 nM 
of Silencer Select Validated siRNA for MCT1 (SLC16A1 
siRNA, s580, Ambion) and MCT4 (SLC16A3 siRNA, 
s17417, Ambion), as well as nontargeting control siRNA 
(Silencer Select Negative Control No.1 siRNA, 4390843, 
Ambion), using 1 μl/ml of Lipofectamine RNAiMAX 
(13778–075, Invitrogen), according to the manufacturer’s 
instructions. For MCT1, total silencing was only observed 
after 1 day, with the reestablishment of the MCT1 
expression at day 2 (48 hours, confirmed by Western Blot, 
Supplementary Figure 1A). For MCT4, total silencing was 
only observed after 72 hours, being maintained for at least 
2 additional days (120 hours, confirmed by Western Blot, 
Supplementary Figure 1B and 1C). The cells were plated 
at day 3 after silencing, when the experiments begin. 
Table 4: Detailed aspects for each antibody used in immunohistochemistry
Protein Antigen retrieval Antibody Antibody dilution and incubation time
MCT1 Citrate buffer (0.01 M, pH = 6), 98° C, 20ʹ AB3538PChemicon International 1:1000, overnight
MCT2 Citrate buffer (0.01 M, pH = 6), 98° C, 20 sc-50322Santa Cruz Biotechnology 1:200, 2 hours
MCT4 Citrate buffer (0.01 M, pH = 6), 98° C, 20ʹ sc-50329Santa Cruz Biotechnology 1:500, 2 hours
CD147 EDTA (1 mM, pH = 8), 98° C, 20’ sc-71038Santa Cruz Biotechnology 1:400, overnight
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Cell biomass analysis 
The effect of MCT4 knockdown on total biomass 
was measured by the Sulforhodamine B assay (TOX-
6, Sigma-Aldrich), according to the manufacturer’s 
instructions. For that, 1.0 × 104 cells/well of silenced 
and negative control cells were plated in 96-wells plates 
in complete DMEM medium culture. Total biomass was 
quantified after 24 hours. Results are represented as 
percentage of total biomass normalized for the control 
condition, of three independent experiments, in triplicate. 
Metabolism assay (extracellular glucose and 
lactate measurements)
The metabolic behavior of MCT4 knockdown JEG-
3 cell line was determined by analyzing the extracellular 
amounts of glucose and lactate. For that, 1.0 × 104 cells/
well of silenced and negative control cells were plated 
in 96-wells plates in complete DMEM medium culture. 
Glucose and lactate measurement were performed after 
24 hours, with commercial kits (Cayman Chemical and 
SpinReact, respectively), according to the manufacturer’s 
instructions. Results are expressed as total μg/total 
biomass of three independent experiments, in triplicate. 
Cell proliferation assay 
The proliferation capacity after silencing of MCT4 
on JEG-3 cell line was assessed by bromodeoxyuridine 
incorporation. For that, 1.0 × 104 cells/well of silenced 
and negative control cells were plated in 96-wells plates 
in complete DMEM medium culture. To determine the 
percentage of proliferation, cells were incubated with 10 
μM bromodeoxyuridine for 24 hours and its incorporation 
was assessed at 370 nm (λref = 492 nm), according to 
the manufacturer’s protocol (Cell Proliferation ELISA, 
BrdU, Roche). Results are represented as percentage of 
proliferation normalized for the control condition, of at 
least three independent experiments, in triplicate. 
Cell death assay
Apoptotic/necrotic cell population was determined 
by Annexin V-FITC Apoptosis Detection Kit I (BD 
Biosciences) according to the manufacturer’s instructions. 
For that, 4.0 × 105 cells/well of silenced and negative 
control cells were plated in 6-wells plates in complete 
DMEM medium culture. After 24 hours, cells were 
collected and Annexin V/PI staining was performed 
with incubation for 15 min at room temperature. The 
percentage of cell death (double staining) was assessed by 
flow cytometry (BD Accuri C6, BD Biosciences), with a 
total of 20000 events collected for each condition. Results 
were analyzed using the BD Accuri C6 Software (version 
1.0.264.21) and are represented as percentage of cell death 
normalized for the control condition, of two independent 
experiments.
Migration assay
Migration capacity of JEG-3 cell line was measured 
using ThinCert Cell Cultures Inserts (Greiner Bio-One), 
according to the manufacturer’s instructions. In brief, 
1.0 × 105 cells/well of silenced and negative control cells 
were plated in 24-well transwell inserts in DMEM, 0% 
FBS. DMEM supplemented with 10% FBS was used as 
chemoattractant. Cells were allowed to migrate for 24 
hours. Then, the cells that did not migrate were removed 
and migrating cells were fixed with methanol and stained 
with hematoxylin and eosin for 10 min. Membranes were 
photographed in Olympus BX43 (×10 magnification), and 
migrating cells were counted using the OpenCFU software 
(version 3.8) [66]. Results are represented as percentage of 
cell migration normalized for the control condition, of two 
independent experiments in duplicate.
Invasion assay
Invasion capacity of JEG-3 cell line was measured 
using Corning BioCoat Matrigel Invasion Chamber 
with BD Matrigel Matrix (Corning), as indicated by the 
manufacturer. In brief, 2.5 × 105 cells/well of silenced and 
negative control cells were plated in the matrigel-coated 
24-well transwell inserts in DMEM, 0% FBS. DMEM 
supplemented with 10% FBS was used as chemoattractant. 
Cells were allowed to invade for 24 hours. Then, the 
noninvading cells were removed and invading cells 
were fixed with methanol and stained with hematoxylin 
and eosin for 10 min. Membranes were photographed in 
Olympus BX43 (×10 magnification), and invading cells 
were counted using the OpenCFU software (version 3.8) 
[66]. Results are represented as percentage of cell invasion 
normalized for the control condition, of at least three 
independent experiments in duplicate. 
Statistical analysis
Results obtained with the human samples were 
analyzed using IBM SPSS Statistics software (version 
23.0, IBM Company, Armonk, NY). ROC curve was used 
to define final score’s cutoff for positivity, based on the 
area under the curve. Frequency of protein expression 
and comparison with clinicopathological data were 
analyzed using McNemar’s test, Pearson’s chi-square 
test and Fisher’s exact test, according to the sample’s 
characteristics. The agreement between TMA and whole 
sections was evaluated by the accuracy of the method. 
Overall and event-free survival curves were constructed 
using Kaplan-Meier’s method and the data compared 
with log-rank test. Cox regression model was used for 
multivariate analysis. In vitro results were analyzed 
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using GraphPad Prism software (version 6.0, GraphPad 
Software, Inc., La Jolla, CA), with Student’s t test (Welch’s 
correction was used in case of unequal variances). For 
all tests, the level of significance was established as 5% 
(significant results if p < 0.05). 
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